e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Regulation of airway pharmacology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Roflumilast N-oxide (RNO) alleviates from RSV-induced loss of ciliated cells and enhanced MUC5AC in differentiated human bronchial epithelial cells (D-HBE)
M. Mata, E. Donet, P. Banyuls, A. Gonzalez-Ramon, J. A. Meledo, I. Martinez-Gonzalez, E. Morcillo, J. Cortijo (Madrid, Spain)
Source:
Annual Congress 2010 - Regulation of airway pharmacology
Session:
Regulation of airway pharmacology
Session type:
Thematic Poster Session
Number:
1244
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Mata, E. Donet, P. Banyuls, A. Gonzalez-Ramon, J. A. Meledo, I. Martinez-Gonzalez, E. Morcillo, J. Cortijo (Madrid, Spain). Roflumilast N-oxide (RNO) alleviates from RSV-induced loss of ciliated cells and enhanced MUC5AC in differentiated human bronchial epithelial cells (D-HBE). Eur Respir J 2010; 36: Suppl. 54, 1244
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Roflumilast N-oxide (RNO) attenuates epithelial-mesenchymal transition (EMT) in differentiated human bronchial epithelial cells (D-HBE)
Source: Annual Congress 2010 - Airway cells as targets for anti-inflammatory drugs
Year: 2010
Modulation of TNFα-induced ICAM-1 expression in a human bronchial epithelial cell line (Beas-2B) by roflumilast N-oxide (RNO), salmeterol (Sal) and budesonide (Bud)
Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II
Year: 2007
Roflumilast N-oxide (RNO) decreases neutrophil adhesion to human bronchial epithelial cells (BEAS-2B) induced by cigarette smoke condensate (CSC)
in vitro
Source: Annual Congress 2010 - Emerging mechanisms in lung injury
Year: 2010
Attenuating effect of tiotropium bromide on IL-8 production from human bronchial epithelial cells, BEAS-2B
in vitro
Source: Annual Congress 2009 - Epithelial cell biology
Year: 2009
Effects of the PDE4 inhibitor roflumilast n-oxide on the adherence of polymorphonuclear cells (PMNC) to bronchial epithelial cells (BEAS-2B) induced by non-typeable
Haemophilus influenzae
Source: Annual Congress 2009 - Highlighting the epithelial cell in lung disease: from COPD to cancer to acute lung injury
Year: 2009
Cytokine-induced production of eotaxin-3 by human lung epithelial cells is inhibited by levocetirizine
Source: Eur Respir J 2005; 26: Suppl. 49, 98s
Year: 2005
Adenovirus E1A suppressed elafin secretion in human bronchial epithelial cells and alveolar epithelial cells
Source: Eur Respir J 2004; 24: Suppl. 48, 554s
Year: 2004
In vitro
modulation of the cytokine-induced human bronchial epithelial cell (HBEC) functions by ciclesonide (CIC)
Source: Eur Respir J 2004; 24: Suppl. 48, 346s
Year: 2004
TGFβ does not induce myofibroblast phenotype in primary human bronchial epithelial cells
Source: Annual Congress 2009 - Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation
Year: 2009
Physiomer(R) reduces the chemokine interleukin-;8 production by activated human respiratory epithelial cells
Source: Eur Respir J 2001; 18: 661-666
Year: 2001
Effect of roflumilast N-oxide on non-typable
haemophilus influenzae
(NTHi) interaction with human airway epithelial A549 cells
Source: Annual Congress 2011 - Epithelial cell biology
Year: 2011
Inhibitory activity of fluticasone propionate (FP), on the constitutive or cytokine-induced bronchial epithelial cell (HBECs) functions
in vitro
Source: Eur Respir J 2003; 22: Suppl. 45, 76s
Year: 2003
Guaifenesin suppresses MUC5AC content and secretion in human airway epithelial cell cultures: Comparison with N-acetylcysteine and ambroxol
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012
Resveratrol impairs cytokine release from human airway smooth muscle cells (HASMCs) and alveolar macrophages (AM) in COPD
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009
Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways
Source: Eur Respir J 2011; 37: 244
Year: 2011
The PDE4 inhibitor roflumilast N-oxide partly reversed TGFß1-induced changes in collagen I and E-cadherin expression in human airway epithelial cells
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008
IL-13 induces glucocorticoid resistance in iNOS expression and activity in human airway epithelial cells (HAECs)
Source: International Congress 2017 – New insights into pathogenesis of lung disease
Year: 2017
Simvastatin selectively inhibits TSLP-production in primary bronchial epithelial cells from COPD donors
Source: Annual Congress 2011 - Translational models of disease
Year: 2011
Effect of s-carboxymethylcysteine on mucin production in airway epithelial cells
in vitro
Source: Eur Respir J 2005; 26: Suppl. 49, 97s
Year: 2005
Inhibition of CFTR-specific miRNAs in CF bronchial epithelial cells
Source: International Congress 2017 – Therapeutic approaches in lung disease
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept